Evidence map›Paper›PMID 19444259›Full record

ReviewNature reviews. Endocrinology2009

Incretin-based therapies for type 2 diabetes mellitus.

Julie A Lovshin, Daniel J Drucker

2 registry-linked trialsAbstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Endocrinology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 279 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
279citing papers in PubMed, 5 pooled it
33.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03959865 unknown statusstarted 2018, after this paper: background citation

Effectiveness and Persistence of Therapy With GLP-1 Receptor Agonists in Clinical Practice. A Multicenter Retrospective Study

Ran2018Enrolled6,000Registered outcomes4Posted comparisons0ConditionsType 2 DiabetesArmsExendin-based GLP-1RA, Fixed ratio BI/GLP-1RA combination, Flexible BI/GLP-1RA combination, Human-based GLP-1RA, Long-acting GLP-1RA
PMID 27717195PMID 27717130PMID 29221659PMID 30291106other papers from this trial
Open the trial in the graph
NCT03165812 naunknown statusnot on this mapstarted 2017, after this paper: background citation

Single Anastomosis Duodeno Jejunal Bypass With Sleeve Gastrectomy (SADJB-SG) Versus Intensive Medical Therapy (IMT) in the Treatment of Type 2 Diabetes Mellitus Among Asian Patients With BMI 23.5 - 30 kg/m2: A Clinical Trial

TypeinterventionalSponsorUniversiti Putra MalaysiaRan2017 to 2019Enrolled84ConditionsDiabetes Mellitus, Type 2, OverweightArmsSADJB-SG group, IMT group
3 · Its place in the literature

Who cites it

279 citing papers in PubMed, 5 syntheses or guidelines pooled it, 647 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Proanthocyanidin-Rich Cranberry Extract Lowers Glycemia in Established Obesity by Delaying Glucose Absorption.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  20. Article

219 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Julie A LovshinDepartment of Medicine, Samuel Lunenfeld Research Institute, Mt Sinai Hospital, University of Toronto, Toronto M5T 3L9, Canada.
Daniel J Drucker
Lunenfeld-Tanenbaum Research Institute · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Incretin-based drugs, such as glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase 4 inhibitors, are now routinely used to treat type 2 diabetes mellitus. These agents regulate glucose metabolism through multiple mechanisms, their use is associated with low rates of hypoglycemia, and they either do not affect body weight (dipeptidyl peptidase 4 inhibitors), or promote weight loss (glucagon-like peptide-1 receptor agonists). The success of exenatide and sitagliptin, the first therapies in their respective drug classes to be based on incretins, has fostered the development of multiple new agents that are currently in late stages of clinical development or awaiting approval. This Review highlights our current understanding of the mechanisms of action of incretin-based drugs, with an emphasis on the emerging clinical profile of new agents.

Indexed as

Diabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsHumansIncretinsReceptors, GlucagonDipeptidyl-Peptidase IV InhibitorsIncretinsReceptors, Glucagon

Identifiers

PMID19444259
OpenAlexW1967256054

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.